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Hematopoietic stem cells (HSCs) residing in the bone
marrow (BM) accumulate during aging but are func-
tionally impaired. However, the role of HSC-intrinsic
and -extrinsic aging mechanisms remains debated.
Megakaryocytes promote quiescence of neighboring
HSCs. Nonetheless, whether megakaryocyte-HSC
interactions change during pathological/natural ag-
ing is unclear. Premature aging in Hutchinson-Gilford
progeria syndrome recapitulates physiological aging
features, butwhether these arise fromaltered stemor
niche cells is unknown. Here, we show that the
BM microenvironment promotes myelopoiesis in
premature/physiological aging. During physiological
aging, HSC-supporting niches decrease near
bone but expand further from bone. Increased BM
noradrenergic innervation promotes b2-adrenergic-
receptor(AR)-interleukin-6-dependent megakaryo-
poiesis. Reduced b3-AR-Nos1 activity correlates
withdecreasedendosteal nichesandmegakaryocyte
apposition to sinusoids. However, chronic treatment
of progeroid mice with b3-AR agonist decreases pre-
mature myeloid and HSC expansion and restores the
proximal association of HSCs to megakaryocytes.Cell Stem Cell 25, 407–418, Septe
This is an open access article undTherefore, normal/premature agingofBMnichespro-
motes myeloid expansion and can be improved by
targeting the microenvironment.
INTRODUCTION
Hematopoietic aging is characterized by expansion of hemato-
poietic stem cells (HSCs) with impaired function, such as
reduced engraftment, quiescence, self-renewal, unfolded protein
response, and lymphoid differentiation potential, leading to
myeloid-biased output both in mice (Liang et al., 2005; Mohrin
et al., 2015; Rossi et al., 2005; Sudo et al., 2000) and humans
(Pang et al., 2011; Rundberg Nilsson et al., 2016). Myeloid malig-
nancies are more frequent in the elderly, but whether changes in
theagedHSCsand/or theirmicroenvironment predispose to these
malignancies remains unclear. HSC aging was initially considered
to result only from intrinsic changes (Dykstra et al., 2011), such as
epigenetic deregulation (Chambers et al., 2007), replication stress
(Flach et al., 2014), deficient DNA repair (Rossi et al., 2007), transi-
tion from canonical to non-canonical Wnt signaling (Florian et al.,
2013), and increased autophagy (Ho et al., 2017). However, aging
also reducesHSCpolarity and capacity to lodge near bone (Ko¨hler
et al., 2009), and microenvironmental alterations have been pro-
posed to contribute to hematopoietic aging. For instance,myeloid
biascan result from telomeredysfunction (Juet al., 2007) or inflam-
matory cytokine production (Ergen et al., 2012) in the agedmber 5, 2019 ª 2019 The Author(s). Published by Elsevier Inc. 407
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Figure 1. Reduction of Endosteal Niches
and Expansion of Non-endosteal Niches
during Aging
(A–B0 and H–I0) Representative whole-mount
immunofluorescent staining of thick femoral sec-
tions for CD31 (A and B, green; H and I, red) and
EMCN (A and B, red; H, I, blue) of young
(8–30 weeks) and old (70–100 weeks) Nes-gfp
mice with genetically labeled nestin+ cells (H and I,
green). Arrowheads in insets (A0, B0, H0, and I0)
depict CD31hiEMCN capillaries and their
coverage by Nes-GFP+ cells.
(C–G) Quantification of (C) CD31hiEMCNhi transi-
tion zone vessels, (D) CD31loEMCNlo sinusoids, (E)
CD31hiEMCN arterioles with R6 mm diameter,
and (F) CD31hiEMCN capillaries with <6 mm
diameter. Scale bar, 200 mm (A, B, H, and I),
100 mm (A0, B0, H0, and I0 ). (G) Frequency of
endosteal and non-endosteal BM Nes-GFP+ cells
from young adult (10–20 weeks, n = 11) and old
mice (>66 weeks, n = 8).
(J–N) Concentration of (J) IL-1b, (K) IL-6, (L) IL-1a,
(M) IL-3, and (N) IFNg in endosteal BM extracel-
lular fluid (BMECF) from young WT mice (n = 5)
and old WT mice (n = 4). Data are means ± SEM.
*p < 0.05; **p < 0.01; ***p < 0.001. (C–F and J–N)
Unpaired two-tailed t test. (G) One-way ANOVA
and Bonferroni pairwise comparisons.hematopoietic microenvironment, and bone marrow (BM) adren-
ergic nerve degeneration has been recently proposed to drive
HSCaging reversibly (Maryanovichetal., 2018).However, the rela-
tive contribution of intrinsic and extrinsic mechanisms to HSC ag-
ing remains debated. Myeloid-biased HSCs (Gekas and Graf,
2013) and more prominently platelet-primed HSCs (Sanjuan-Pla
et al., 2013; Yamamoto et al., 2013) expand in aged mice (Grover
et al., 2016). However, both platelet-primed and unprimed old
HSCs exhibit myeloid bias (Grover et al., 2016), possibly suggest-
ing a microenvironmental participation. The standard model of
platelet generation (thrombopoiesis) suggests that megakaryo-
cyteprecursorsmigrate fromendostealBM (close tobone) tosinu-
soids (further frombone) formaturation (Eto andKunishima, 2016),
which can be promoted by cytokines like interleukin (IL)-1a IL-1b,
IL-6, IL-3, and interferon-gamma (IFNg) (Pietras, 2017). Whereas
platelet-biased HSCs are located near sinusoids (Pinho et al.,
2018), both megakaryocytes and their precursors have been
recently found throughout BM, including the sinusoids where
megakaryocyte maturation and thrombopoiesis take place (Plo
et al., 2017; Stegner et al., 2017). In this study, we have investi-408 Cell Stem Cell 25, 407–418, September 5, 2019gated whether different BMmicroenviron-
ments regulate myeloid differentiation and
megakaryopoiesis during aging.
RESULTS
Reduction of Endosteal Niches and
Expansion of Non-endosteal
Neurovascular Niches during Aging
To characterize changes in vascular beds
during aging, we performed whole-mount
immunofluorescence staining of thickfemoral sections of young and old wild type (WT) mice using
CD31 and endomucin (EMCN) to identify sinusoids, arterioles,
capillaries, and transition zone vessels (TZVs), which connect ar-
terioles with sinusoids near bone (endosteum). Consistent with
previous findings (Kusumbe et al., 2016), endosteal vessels
and TZVs were reduced in old mice; however, we also noted
that, whereas sinusoidal areas appeared unchanged, arterioles
were slightly reduced and capillaries located further from bone
increased 4-fold in old mice (Figures 1A–1F). These vascular
changes were paralleled by similar alterations of their associated
perivascular cells. We used Nes-gfp transgenic mice, which
carry HSC niche-forming perivascular BM mesenchymal stem
or progenitor cells (BMSCs) labeled with GFP (Me´ndez-Ferrer
et al., 2010b). Nes-GFP+ cells augmented 4-fold specifically in
non-endosteal BM, mostly associated with the increased capil-
laries (Figures 1G–1I and S1A–S1D). These changes correlated
with increased inflammatory cytokines that drive myeloid cell
expansion (Pietras, 2017). The concentration of IL-1a, IL-1b,
and IL-6 increased in the BM during aging, whereas IL-3 and
IFNg showed similar trends (Figures 1J–1N and S1M-S1Q).
Figure 2. Increased Sympathetic Nerve Fi-
bers during Aging
(A, B, E, and F) Immunofluorescence of tyrosine
hydroxylase (TH)+ sympathetic noradrenergic
nerve fibers (white), CD31+ endothelial cells (red),
and GFP+ cells (green) in the skull (A and B) and
tibial (E and F) BM of young (A and E) and old
(B and F) Nes-gfp mice. Scale bar, 100 mm.
(C and D) Area covered by TH+ fibers in the (C)
skull or (D) tibia of young (n = 12) and old (n = 8)
Nes-gfp mice. Young mice were analyzed be-
tween 8–30 weeks of age, and old mice were 66–
120 weeks old. Data are means ± SEM. *p < 0.05;
**p < 0.01 (unpaired two-tailed t test).We have previously shown that sympathetic adrenergic
signals regulate Nes-GFP+ cell proliferation (Me´ndez-Ferrer
et al., 2010b) and are affected during age-related myeloprolif-
erative neoplasms (Arranz et al., 2014). Additionally, increased
sympathetic adrenergic activity has been previously
described during aging (Hart and Charkoudian, 2014; Ng
et al., 1993; Veith et al., 1986; Ziegler et al., 1976), chronic
stress, and depression (Yirmiya et al., 2006), and might in-
crease osteoporosis and fracture risk by restraining bone for-
mation (Elefteriou et al., 2005; Takeda et al., 2002). However,
the opposite (decreased BM adrenergic innervation) has been
recently suggested as causative of HSC aging (Maryanovich
et al., 2018). To clarify this, whole-mount preparations of
skulls and thick tibial sections of Nes-gfp mice were immuno-
stained for tyrosine hydroxylase (TH), to visualize sympathetic
noradrenergic fibers and nestin+ cells in large 3D volumes.
This study did not confirm reduced TH+ fibers in the aged
BM (Maryanovich et al., 2018) but found these fibers
increased by 50% in the skull of old mice (Figures 2A–2C)
and augmented 2.5-fold in the aged tibial BM, compared
with the young samples (Figures 2D–2F). In both cases,
nestin+ cells were found in proximity of noradrenergic
fibers (Figures S1E–S1L). Together, these results suggest
contraction of endosteal (bone-associated) HSC niches and
expansion of non-endosteal neurovascular HSC niches during
aging.Cell Stemb-Adrenergic Signals Promote
Megakaryopoiesis during Aging
To study the possible contribution of
increased adrenergic innervation to
aged hematopoiesis, we analyzed mice
lacking b2-AR and b3-AR (Adrb2
/
Adrb3/), the main b-ARs that
cooperate in HSC niche regulation (Me´n-
dez-Ferrer et al., 2010a). Importantly,
myeloid and megakaryocyte progenitors
expanded less in the endosteal BM of
aged Adrb2/Adrb3/ mice (Figures
3A, 3B, and S2A–S2F). Consequently,
megakaryocytes did not increase in
Adrb2/Adrb3/ mice during aging
(Figures 3C–3G), suggesting a functional
role for increased noradrenergic signaling
in aged hematopoiesis. Megakaryocyteswere less frequently found in apposition to BM sinusoids and
could form less protrusions (required for proplatelet formation)
in aged Adrb2/Adrb3/ mice (Figures 3H–3M). Accordingly,
aged Adrb2/Adrb3/ mice did not show the increased circu-
lating platelets typically observed in aged WT mice (Figure 3N),
whereas other circulating blood cell types remained unaffected
(Figures S2G–S2J). These results suggest that increased
b-adrenergic signaling in the BM promotes myeloid differentia-
tion into platelets during aging.
b2-AR in the Microenvironment Promotes
Megakaryocyte Differentiation
We analyzed single Adrb2/ mice and Adrb3/ mice to un-
derstand the role of each b-AR in myelopoietic regulation.
Resembling aged Adrb2/Adrb3/ mice (Figure 3N), aged
Adrb2/ mice did not exhibit increased circulating platelets
(Figure 4A), suggesting that increased b2-adrenergic activity
promotes thrombopoiesis during aging. Already at adulthood,
Adrb2/ mice showed reduced frequency of myeloid and
megakaryocyte progenitors, and this reduction persisted
during aging (Figures 4B, 4C, S3A, and S3B). We generated
BM chimeras using Adrb2/ mice or WT mice as donors/re-
cipients to distinguish hematopoietic cell-autonomous from
microenvironmental regulation. WT mice carrying b2-AR-defi-
cient hematopoietic cells showed normal frequencies of
myeloid and megakaryocyte progenitors (Figures 4B0–4C0Cell 25, 407–418, September 5, 2019 409
Figure 3. b-Adrenergic Signals Promote
Megakaryopoiesis during Aging
(A and B) Representative flow chart (A) and
quantification (B) of the frequency of CD41+
myeloid or megakaryocyte progenitors within
linsca-1+c-kit+ (LSK) cells in endosteal BM from
young WT mice (n = 7), young Adrb2/Adrb3/
(double knockout [DKO]) mice (n = 7), old WT mice
(n = 5), and old Adrb2/Adrb3/ mice (n = 4).
(C–F) Representative immunofluorescence stain-
ing for CD41 (red) and CD42 (green) in femoral BM
sections of young (C) or old (D)WTmice and young
(E) or old (F) Adrb2/Adrb3/ mice. Arrowheads
depict megakaryocytes with protrusions (CD41+
CD42+ cells with cell body extensions). Scale bar,
250 mm.
(G and H) Number of CD41+CD42+ megakaryo-
cytes (G) forming protrusions (H) per BM area
(n = 4 youngWT; n = 5 young DKO; n = 3 old mice).
(I–L) Representative immunofluorescence staining
for CD41 (red) and EMCN (green) in femoral BM
sections of young (I) or old (J) WT mice and young
(K) or old (L) Adrb2/Adrb3/ mice, depicting
CD41+ megakaryocytes adjacent (arrowheads) or
nonadjacent (asterisks) to EMCN+ vasculature.
Scale bar, 100 mm.
(M) Frequency of CD41+ cells in contact with
EMCN+ vasculature (n = 4 young WT; n = 4 young
DKO; n = 4 old WT; n = 3 old DKO).
(N) Circulating platelets in young (n = 11) and old
(n = 6) WT mice, compared with young (n = 9) and
old (n = 5) Adrb2/Adrb3/ mice. Young mice
were analyzed between 8–30 weeks of age, and
old mice were 66–120 weeks old. Data are
means ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001
(one-way ANOVA followed by Bonferroni pairwise
comparisons).and S3A0–S3B0). In contrast, Adrb2/ recipients of WT BM
cells showed similar reductions as found in primary mice
(Figures 4B00–4C00 and S3A00–S3B00). These results suggest
that b2-AR signals promote megakaryocyte differentiation
through the microenvironment. To obtain mechanistic insight,
we treated with selective b2-AR or b3-AR agonists the
HSPC-like HPC-7 cell line (Pinto do O et al., 1998) cultured
alone or co-cultured with MS-5 stromal cells, which resemble
nestin+ BMSCs (Me´ndez-Ferrer et al., 2008, 2010b; Figures
S3C and S3D). Whereas the selective b-AR agonists did not
affect megakaryocyte differentiation of HPC-7 cells cultured
alone (Figure S3E), b2-AR and b3-AR agonists had opposite
stage-specific effects on megakaryocytic differentiation from
HPC-7 cells co-cultured with MS-5 cells. Whereas b3-AR
agonist increased the frequency of undifferentiated c-kithi
CD41lo cells and decreased the fraction of c-kitloCD41lo
megakaryocyte progenitors, b2-AR agonist did not affect
early differentiation, but instead increased the frequency of
CD41hi megakaryocytic cells at a later differentiation stage
(Figure S3F).410 Cell Stem Cell 25, 407–418, September 5, 2019To test the potential significance of
this regulation in the human setting, we
treated human umbilical cord blood-
derived hCD34+ HSPCs co-culturedwith MS-5 cells with a selective b2-AR agonist (Figure 4D). Treat-
ment with b2-AR agonist increased the frequency of human
CD61+megakaryocytic cells (Figures 4E–4G). These results sug-
gest that b2-AR stimulation of stromal cells promotes megakar-
yocyte differentiation.
b2-AR Indirectly Promotes Megakaryocyte
Differentiation through IL-6
To investigate the underlying mechanism, we measured several
cytokines which regulate megakaryopoiesis. Among those, IL-6
concentration increased in WT BM during aging (Figure 1H) and
was low in endosteal Adrb2/ BM (Figures 4H and S3G–S3I).
Moreover, b2-AR agonist increased Il6 mRNA 2-fold in MS-5
stromal cells; this effect was abrogated after blocking protein ki-
nase A (Figure 4I) downstream of b2-AR signaling (Rosenbaum
et al., 2009). Adult Adrb2/ mice and Il6/ mice showed simi-
larly reduced BM megakaryocytes (Figures 4J–4M), confirming
the role of b2-AR and IL6 in megakaryopoiesis. To directly test
the role of IL-6 downstream of b2-AR, we established primary
BM cultures from Il6/ or control mice and treated them with
Figure 4. b2-AR Signaling in the Microenvi-
ronment Promotes Megakaryocyte Differen-
tiation through IL-6
(A) Circulating platelets in youngWT (n = 11), young
Adrb2/ (n = 3), or old Adrb2/ (n = 3) mice.
(B–C00) Frequency of (B, B0, and B00) CD41+
myeloid or megakaryocyte progenitors within
linsca-1+c-kit+ (LSK) cells or (C, C0, and C00)
CD150+CD41+ megakaryocyte progenitors (MkPs)
within linc-kit+ (LK) cells in endosteal BM cells of
the following mice: (B and C) youngWT (B, n = 6; C,
n = 3), young Adrb2/ (B, n = 6; C, n = 8) or old
Adrb2/ (n = 4) mice; (B0 and C0) lethally irradiated
WT recipients of WT (n = 5) or Adrb2/ (n = 4) BM
cells; (B00 and C00) lethally irradiated WT (n = 5) or
Adrb2/ (n = 4) recipients of WT BM cells.
(D) Scheme of human umbilical-cord-blood-
derived CD34+ HSPCs cocultured with MS-5 stro-
mal cells.
(E–G) Representative immunofluorescence (E and
F) and number (G) of CD61+ (red) human mega-
karyocytes in cocultures treated with (E) vehicle or
(F) b2-AR agonist (clenbuterol, 10 mM) for 10 days
(n = 3). Scale bar, 250 mm. (F0) Inset of (F).
(H) IL6 concentration in endosteal (e) or non-
endosteal (n-e) BM supernatant from adult WT
(n = 6), Adrb2/ (n = 4), or Adrb3/ (n = 7) mice.
(I) Il6 mRNA expression (fold change) in MS-5
stromal cells treated with b2-AR agonist (clenbu-
terol, 10 mM), PKA inhibitor (H-89, 5 mM), or vehicle
for 2 days (n = 3).
(J–M) Quantification (J) and representative immu-
nofluorescence (K–M) of CD41+ (red) CD42+ (green)
megakaryocytes (yellow) in adult WT (n = 5),
Adrb2/ (n = 3), or Il6/ (n = 5) mice. Scale bar,
250 mm.
(N) Myeloid or megakaryocyte progenitors (CD41+
LSK cells) in primary BM culture from WT or Il6/
mice treated with b2-AR agonist (clenbuterol,
10 mM) or vehicle for 4 days (n = 4). Data are
means ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001.
(B0, B00, C0, C00, and G) Unpaired two-tailed t test.
(A, B, C, H, I, J, and N) one-way ANOVA and Bon-
ferroni pairwise comparisons.b2-AR agonist or vehicle. b2-AR agonist tripled myeloid progen-
itors in WT samples, but not in Il6/ samples (Figure 4N). Alto-
gether, these results suggest that b2-AR on stromal cells
promotes megakaryocyte differentiation through IL-6.
b3-AR-Deficient Mice Exhibit Altered HSC Lineage Bias
Our co-culture experiments suggested that, contrasting b2-AR,
b3-AR might inhibit megakaryocytic differentiation (Figures
S3C–S3F). Additionally, b3-AR stimulation has been shown to
promote HSC lymphoid skewing (Maryanovich et al., 2018).
Therefore, wemeasured the frequency of immunophenotypically
defined lymphoid-biased HSCs (Figure S4A; Yamamoto et al.,
2013). Lymphoid-biased HSCs were reduced by one-third in
adult endosteal Adrb3/ BM (Figures 5A and S4B). This pheno-
type was not observed in WT mice carrying b3-AR-deficient he-
matopoietic cells (Figures 5A0 and S4B0) but was reproduced in
chimeric mice lacking b3-AR in the microenvironment (Figures5A00 and S4B00), implying niche-mediated regulation. Opposite
trends were observed for long-term HSCs (LT-HSCs) and
myeloid-biased HSCs, with their frequencies tending to increase
in endosteal Adrb3/ BM (Figures S4C–S4F). These results
suggest accelerated lymphoid deficiency in the endosteal micro-
environment lacking b3-AR.
We investigated possible mechanisms that might explain the
intriguingly opposite effects of b3-AR and b2-AR signaling on
lympho-myeloid lineage skewing. Whereas both b-ARs can acti-
vate G proteins (Rosenbaum et al., 2009), their differential
cardiovascular effects have been attributed to b3-AR-dependent
nitric oxide (NO) generation (Gauthier et al., 1998). Therefore, we
measured nitrate concentration in the BM extracellular fluid and
found it doubled in endosteal (compared with non-endosteal)
WT BM and halved in Adrb3/ BM (Figure 5B). Among NO syn-
thases, Nos1 (but not Nos2 or Nos3) showed higher mRNA
expression in endosteal WT BM and was downregulated inCell Stem Cell 25, 407–418, September 5, 2019 411
Figure 5. Lack of b3-AR and Nitric Oxide
Synthase 1 (Nos1) Signaling in the Microen-
vironment Accelerates Aging
(A, A0, and A00) Frequency of CD150lo/CD41
lymphoid-biased HSCs in endosteal BM
CD34LSK cells from the following mice: (A) young
WT (n = 7), young Adrb3/ (n = 7), or old Adrb3/
(n = 5) mice; (A0) lethally irradiated WT recipients of
WT (n = 5) or Adrb3/ (n = 5) BM cells; and (A00)
lethally irradiated WT (n = 4) or Adrb3/ (n = 3)
recipients of WT BM cells.
(B) Nitrate concentration in BM extracellular fluid
(BMECF) of young WT (n = 6) or Adrb3/ (n = 7)
mice.
(C) Number of linsca-1+c-kit+CD34CD48
CD150+Vwf-eGFP lymphoid-biased HSCs in pri-
mary BM culture from Vwf-eGFPmice treated with
b3-AR agonist (BRL37344, 10 mM), Nos1 inhibitor
(L-VINO, 100 mM), or vehicle for 4 days (n = 8).
(D–G) Representative immunofluorescence (D–F)
and quantification (G) of c-kit+ (green) CD41+ (red)
myeloid or megakaryocyte progenitors (arrow-
heads) in endosteal BM of WT (n = 10), Adrb3/
(n = 8), or Nos1/ (n = 4) mice. Endosteal BM is
considered as regions within one-fifth marrow
width from the bone surface. Scale bar, 300 mm.
(H–K) Representative immunofluorescence (H-J)
and quantification (K) of CD41+ (red) megakaryo-
cytes adjacent (arrowheads) or nonadjacent (as-
terisks) to EMCN+ (green) BM vasculature of WT
(n = 9), Adrb3/ (n = 6), or Nos1/ (n = 4) mice.
Scale bar, 250 mm.
(L–N0) Representative whole-mount immunofluo-
rescence of CD31 (green) and EMCN (red) in WT
(n = 7), Adrb3/ (n = 5), or Nos1/ (n = 4) BM.
Arrowheads in insets (L0), (M0 ), and (N0) depict
CD31hiEMCN capillaries.
(O and P) Quantification of (O) CD31hiEMCNhi
transition zone vessels and (P) CD31hiEMCN
capillaries with <6 mmdiameter. Scale bar, 250 mm.
Data are means ± SEM. *p < 0.05; **p < 0.01;
***p < 0.001. (A0 and A00) Unpaired two-tailed t test.
(A–C, G, K, O, and P) One-way ANOVA and Bon-
ferroni pairwise comparisons.Adrb3/ BM (Figures S4G–S4I). To further study the role of
b3-AR and Nos1 on HSC lineage bias, we established primary
BM cultures from transgenicmice expressing GFP under the reg-
ulatory elements of Von Willebrand factor (Vwf-eGFP), which
discriminate myeloid/platelet-biased (Vwf-eGFP+) HSCs from
lymphoid-biased (Vwf-eGFP) HSCs (Sanjuan-Pla et al., 2013).
Treatment with b3-AR agonist did not affect platelet-biased
HSCs (Figures S4J and S4K) but doubled lymphoid-biased
HSCs in a Nos1-dependent manner (Figure 5C). Moreover,
Adrb3/mice andNos1/mice showed similar signs of prema-
ture hematopoietic aging; myeloid or megakaryocyte progenitors
(Figures 5D–5G) and megakaryocyte apposition to blood vessels
(Figures 5H–5K) similarly increased in adult Adrb3/ mice and
Nos1/ mice. Consistently, transition zone vessels decreased
(Figures 5L–5O) whereas capillaries expanded (Figure 5P) in
both KO models. Despite the partial reduction of lymphoid-
biasedHSCs in endostealAdrb3/BM, the frequencies of circu-412 Cell Stem Cell 25, 407–418, September 5, 2019lating lymphocytes or myeloid cells appeared unchanged in
5-month-old Adrb3/ mice (Figures S4L–S4N), contrasting pre-
vious findings (Maryanovich et al., 2018). Whereas adult
Adrb3/ mice did not yet show in our analysis premature he-
matopoietic aging in peripheral blood, adult Nos1/ mice
showed reduced lymphocytes and increased neutrophils and
platelets in circulation (Figures 6A and 6B), suggesting that other
pathways (besides b3-AR) contribute to Nos1-dependent regula-
tion of hematopoiesis. Altogether, these results suggest that
microenvironmental b3-AR contributes to balance HSC lineage-
bias toward lymphoid production, which is at least partially
dependent on Nos1-dependent NO production.
Premature Hematopoietic Aging in HGPS Is Not HSC-
Autonomous
We next interrogated whether the BM microenvironment might
promote pathological (and not only physiological) hematopoietic
Figure 6. Premature Hematopoietic Aging
in HGPS Is Not HSC-Autonomous
(A–D) Peripheral blood counts in adult (A and B)
WT (Nos1+/+; n = 15) or Nos1/ (n = 16), and
(C and D) WT (Lmna+/+; n = 22) or LmnaG609G/G609G
(n = 14) mice. (A, C, and K) Frequency of white
blood cells (WBC); LYM, lymphocytes; MON,
monocytes; NEU, neutrophils. (B, D, and L) Con-
centration of platelets.
(E–G) Frequency of (E) CD11b+ myeloid cells, (F)
B220+ B cells, and (G) CD3+ T cells in circulating
leukocytes.
(H–J) Frequency of (H) CD11b+ myeloid cells, (I)
B220+ B cells, and (J) CD3+ T cells among donor-
derived leukocytes 120 days after transplantation
into WT mice (n = 11).
(K and L) Peripheral white blood cell (K) and
platelet (L) counts in adult CD45.1 C57BL/6J mice
4 months after lethal irradiation and trans-
plantation with CD45.2 BM cells fromWT (n = 8) or
LmnaG609G/G609G (n = 6) mice.
(M–Q) Concentration of (M) IL-1b, (N) IL-6, (O)
IL-1a, (P) IL-3, and (Q) IFNg in the BM extracellular
fluid (BMECF) of adult WT (Lmna+/+; n = 9) and
LmnaG609G/G609G (n = 9) male mice. Data are
means ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001
(unpaired two-tailed t test).aging. Premature aging in Hutchinson-Gilford progeria syn-
drome (HGPS) is caused by the accumulation of a truncated
prelamin A protein named ‘‘progerin,’’ which is produced via
aberrant splicing resulting from a de novo synonymous
c.1824C > T (p.G608G) point mutation in the LMNA gene (encod-
ing lamin A and C) (De Sandre-Giovannoli et al., 2003; Eriksson
et al., 2003). This gene has been recently associated with
changes in epigenetic and chromatin architecture in aged
HSCs (Grigoryan et al., 2018). Progerin also accumulates during
normal aging and HGPS displays most aging hallmarks,
suggesting that HGPS can inform physiological aging
(Lo´pez-Otı´n et al., 2013). LmnaG609G knockin mice exhibit key
hallmarks of the human disease, including accelerated aging,
shortened lifespan, and bone and cardiovascular defectsCell Stem(Hamczyk et al., 2018; Osorio et al.,
2011; Villa-Bellosta et al., 2013). Certain
hallmarks of hematopoietic aging in
mice, such as increased circulating plate-
lets, have been observed in HGPS (Meri-
deth et al., 2008). However, it remains
unknown whether premature aging af-
fects the overall hematopoietic system
in HGPS and whether this is a conse-
quence of the LMNA mutation in HSCs,
other hematopoietic cells and/or their
microenvironment.
We measured peripheral blood counts
in progeroid mice and control mice.
Remarkably, adult progeroid mice
resembled adult Nos1/ mice (Figures
6A and 6B) in their premature myeloid
skewing evidenced by decreased lym-phocytes and increased neutrophils, monocytes, and platelets
(Figures 6C and 6D), to a similar extent as normally aged mice
(Dykstra et al., 2011; Rossi et al., 2005; Sudo et al., 2000).
Flow cytometry analysis confirmed increased myeloid cells and
decreased lymphoid cells in the peripheral blood of progeroid
mice (Figures 6E–6G).
To test HSC function, lethally irradiated CD45.1 recipients
were transplanted with CD45.2 BM cells from LmnaG609G/G609G
mice or WT mice, together with competitor BM cells from con-
genic CD45.1 mice (Figure S5A). Long-term engraftment was
lower for LmnaG609G/G609G (compared with WT) hematopoietic
cells (Figure S5B), as previously observed for normally aged
HSCs (Liang et al., 2005), albeit to a lower extent. However,
myeloid skewing was not observed in blood cells derived fromCell 25, 407–418, September 5, 2019 413
Figure 7. b3-AR Agonist Improves Lineage Skewing, HSC Number,
and Localization near Megakaryocytes in HGPS
(A and B) Frequency of (A) granulocytes and (B) lymphocytes in white blood
cells (WBCs) of WT mice (n = 8) or LmnaG609G/G609G mice (n = 6) treated with
b3-AR agonist (BRL37344, 2 mg/kg/day, intraperitoneally [i.p.]) or vehicle for
8 weeks.
(C–F) Frequency of BM (C) Ly6G+CD11b+ neutrophils, (D) B220+ B cells,
endosteal (E), and non-endosteal (F) LT-HSCs in these mice (n = 6).
(G–J) Representative immunofluorescence (G–I) and quantification (J) of
CD41+ megakaryocytes adjacent (asterisks) or nonadjacent (arrowheads) to
c-kit+ (green) HSPCs in BM of WT mice (n = 3) and LmnaG609G/G609G mice
(n = 5) treated with b3-AR agonist or vehicle. Scale bar, 50 mm.
(K–N) Representative immunofluorescence (K–M) and distribution (N) of
BM CD150+ (red) HSCs (negative for mature hematopoietic lineage
markers, blue) adjacent (asterisks), or nonadjacent (arrows) to CD42+
(green) megakaryocytes. Scale bar, 50 mm. Data are means ± SEM.
*p < 0.05; **p < 0.01; ***p < 0.001. (A–F and J) One-way ANOVA and
Bonferroni pairwise comparisons. (N) Two-way ANOVA and Bonferroni
pairwise comparisons.
414 Cell Stem Cell 25, 407–418, September 5, 2019LmnaG609G/G609GHSCs (Figures 6H–6J), suggesting thatmyeloid
skewing is a non-HSC-autonomous aging feature in HGPS. To
assess this possibility, we transplanted CD45.2 BM cells from
LmnaG609G/G609G mice into lethally irradiated CD45.1 WT
recipients. Sixteen weeks later, WT recipients carrying the
LmnaG609G/G609G mutation only in hematopoietic cells (Figures
6K and 6L) did not reproduce themyeloid skewing and increased
platelet counts observed in constitutive LmnaG609G/G609G mice
(Figures 6C and 6D). Together, these results suggest that prema-
ture aging in HGPS affects the hematopoietic system but cannot
be explained by HSC-autonomous alterations. Consistent with
this idea, microenvironmental alterations (such as sinusoidal
vasodilation) were found in LmnaG609G/G609G BM (Figures S5D
and S5E). Moreover, myelopoietic cytokines augmented in nor-
mally aged BM microenvironment (Figures 1J–1N) were also
increased in adult progeroid mice (Figures 6M–6Q).
These results suggested that similar microenvironmental alter-
ations might promote myeloid differentiation during physiolog-
ical/pathological aging. Therefore, we tested whether targeting
the microenvironment could impact hematopoiesis in HGPS.
Progeroid mice were chronically treated with a b3-AR agonist,
which can rescue nestin+ niches in humans and mice with age-
related myeloproliferative disorders (Arranz et al., 2014; Drexler
et al., 2019) and has been recently suggested to rejuvenate nor-
mally aged HSCs (Maryanovich et al., 2018). Treatment with
b3-AR agonist over 2 months normalized circulating granulo-
cytes and lymphocytes and BMneutrophils and partially rescued
BM B cells (Figures 7A–7D). This effect correlated with
decreased frequency of BM LT-HSCs (Figures 7E and 7F).
Megakaryocytes have been shown to regulate HSC prolifera-
tion (Bruns et al., 2014; Nakamura-Ishizu et al., 2015; Zhao et al.,
2014) and their numbers were found to increase during normal/
pathological aging in this study. Therefore, we examined the
spatial relationships between megakaryocytes and HSPCs in
the different models. Like in aged mice (Maryanovich et al.,
2018), HSCs expanded but located further frommegakaryocytes
in adult Adrb3/mice, as an additional premature aging
feature in these mice (Figures S6A–S6D). Increased LT-HSC fre-
quency in vehicle-treated progeroid mice (compared with WT
mice) (Figures 7E and 7F) correlatedwith reduced co-localization
of HSPCs and megakaryocytes, which was rescued by b3-AR
agonist (Figures 7G–7J). HSCs located more distantly from
megakaryocytes in vehicle-treated progeroid mice (compared
with WT mice) but this association was partially restored by
b3-AR agonist (Figures 7K–7N). These results suggest the possi-
bility that decreased interactions between megakaryocytes and
HSCs might reversibly regulate hematopoiesis during aging.
DISCUSSION
This study suggests that alterations of the BM microenviron-
ment during pathological/physiological aging change hemato-
poiesis. Remodeling of BM HSC niches (namely reduced
endosteal niches and increased non-endosteal neurovascular
niches) is associated with the overproduction of pro-in-
flammatory cytokines which drive excessive myelopoiesis in
normal/premature aging. However, the latter can be improved
by modulating the microenvironment. Together, these
results expand previous findings on the microenvironmental
contribution to hematopoietic aging to the role of different neu-
rovascular beds in normal and pathological aging, and their po-
tential therapeutic targeting.
Stem cell aging compromises tissue turnover and regenera-
tion, but the contribution of the aged stem cell niche remains
incompletely understood (Lo´pez-Otı´n et al., 2013). In the he-
matopoietic system, HSCs expand during aging but exhibit
impaired self-renewal and lymphoid differentiation potential, fa-
voring myeloid output (Liang et al., 2005; Mohrin et al., 2015;
Pang et al., 2011; Rossi et al., 2005; Rundberg Nilsson et al.,
2016; Sudo et al., 2000). Moreover, myeloid malignancies are
more frequent in the elderly, but whether changes in the aged
HSCs and/or their microenvironment predispose to these malig-
nancies has remained unclear. Although HSC aging was initially
regarded as solely derived from intrinsic changes in HSCs
(Chambers et al., 2007; Dykstra et al., 2011; Florian et al.,
2013; Rossi et al., 2007), several alterations in the BM microen-
vironment or in its interaction with HSCs have been proposed to
promote hematopoietic aging (Ergen et al., 2012; Ju et al., 2007;
Ko¨hler et al., 2009; Maryanovich et al., 2018). Our study supports
this contention by demonstrating that changes in the microenvi-
ronment contribute to physiological hematopoietic aging and
pathological premature aging (HGPS). In both settings, the
aged microenvironment promotes myeloid differentiation
through similar cytokines, such as IL-1b and IL-6.
Progeroid mice exhibit several hallmarks of hematopoietic ag-
ing: expanded HSCs with reduced engraftment, lymphoid defi-
ciency, and myeloid skewing toward platelets. However,
chimeric mice carrying LmnaG609G/G609G hematopoietic cells in
a WT environment do not reproduce the hematopoietic aging of
progeroid mice. Together with the altered vasculature and
increased concentration of myelopoietic cytokines in progeroid
BM, these results strongly suggest that the BM microenviron-
ment causes premature hematopoietic aging in HGPS. In fact,
chronic treatment of progeroidmicewithb3-ARagonist (targeting
the microenvironment) reduces HSCs and restores their prox-
imity to megakaryocytes and their lympho-myeloid skewing.
During physiological aging, endosteal BM niches decrease,
consistent with previous observations (Kusumbe et al., 2016),
whereas non-endosteal neurovascular BM niches containing
Nes-GFP+ stromal cells show a pronounced expansion. This
microenvironmental remodeling might directly favor myeloid
expansion during aging, because lymphoid niches have been
found near bone (Morrison and Scadden, 2014), whereas
myeloid cell expansion and thrombopoiesis mainly occurs in
non-endosteal niches (Eto and Kunishima, 2016).
Recently, an age-related reduction of BM adrenergic nerve fi-
bers has been reported to dive most hallmarks of HSC aging
(Maryanovich et al., 2018). However, studies on BM innervation
during aging have provided conflicting results, with BM adren-
ergic fibers reportedly been dramatically reduced (Maryanovich
et al., 2018), unchanged, or increased (Chartier et al., 2018). The
whole-mount or thick section imaging and 3D reconstruction of
different bones in the present study supports the latter and dem-
onstrates that these fibers are doubled in different bones during
physiological aging. Moreover, these fibers are not reduced in
adult progeroid mice (Figure S7), which exhibit premature he-
matopoietic aging. Our findings are consistent with the well-
known increase in sympathetic activity in the elderly (Hart andCharkoudian, 2014; Ng et al., 1993; Veith et al., 1986; Ziegler
et al., 1976) and suggest a functional change of neurotransmis-
sion (b2-AR overriding b3-AR), rather than a general decline of
BM innervation during aging. Actually, increased noradrenergic
activity in the BM seems to account for augmented thrombopoi-
esis in aged mice because platelets are not elevated in aged
Adrb2/ mice or Adrb2/Adrb3/ mice. A previous study
showed direct effects of a-ARs on mature megakaryocyte adhe-
sion, proplatelet formation, and platelet release, whereas a-AR
signaling on more primitive CD34+ progenitor cells did not affect
lineage commitment (Chen et al., 2016). However, the present
study indicates that HSPC lineage commitment is regulated by
the microenvironment through b2-AR and b3-AR. Therefore,
BM noradrenergic activity appears to regulate lineage commit-
ment and megakaryopoiesis at different stages of maturation
through distinct a- and b-ARs. Interestingly, b2-AR and b3-AR
exhibit opposite roles on myeloid differentiation: whereas
b2-AR signaling promotes megakaryopoiesis through stromal-
cell-derived IL6 and becomes predominant during aging,
b3-AR inhibits myelopoiesis. Lack of b2-AR in the microenviron-
ment (but not in the hematopoietic system) halves myeloid and
megakaryocyte progenitors in adult mice. Decreased frequency
of megakaryocyte lineage cells is similarly found in adult
Adrb2/ mice and aged Adrb2/Adrb3/ mice (but not in
WT chimeras carrying Adrb2/ hematopoietic cells), suggest-
ing that predominant b2-AR activation promotes megakaryocyte
differentiation during aging. Whereas adult Adrb2/ mice and
Adrb3/ mice exhibit opposite deregulation of lymphoid/
myeloid lineage output, only Adrb2/ mice retain this pheno-
type upon aging (Figures 4B, 4C, and 5A), further suggesting
that b2-AR prevails over b3-AR in hematopoietic lineage regula-
tion during aging. This regulation requires IL-6, a cytokine known
to increase in elderly humans (Brusnahan et al., 2010) and to be
similarly regulated in other cell types (Li et al., 2013). Supporting
the role of IL6, megakaryocytes appear decreased in Il6/ BM.
Moreover, b2-AR agonist specifically increased IL-6 expression
in stromal cells co-cultured with human/murine HSPCs and
consequently stimulates megakaryopoiesis in these co-cultures
or in primary BM cultures from WT mice, but not Il6/ mice.
In contrast, microenvironmental (but not hematopoietic) lack
of b3-AR partially reduces lymphoid-biased HSCs in adult
mice, as previously reported (Maryanovich et al., 2018). How-
ever, the results here differ in that b3-AR loss does not appear
overall sufficient to cause premature hematopoietic aging,
because the frequencies of circulating lymphocytes and myeloid
cells appeared unchanged in 5-month-old Adrb3/ mice.
In vitro, b3-AR agonist-treated stromal cells decrease human
and murine HSPC differentiation into megakaryocytes. This ef-
fect requires Nos1, because Nos1/ mice have high circulating
platelets and granulocytes, but low circulating lymphocytes.
Furthermore, b3-AR agonist specifically increases lymphoid-
biased HSCs in primary BM cultures in a Nos1-dependent
manner. Moreover, adult Adrb3/ or Nos1/ mice share pre-
mature microenvironmental aging features in the BM, such as
reduced bone-forming transition zone vessels (Kusumbe et al.,
2016) and increased BM capillaries, myeloid progenitors, and
megakaryocyte apposition to blood vessels.
Megakaryocytes inhibit HSC proliferation (Bruns et al., 2014;
Nakamura-Ishizu et al., 2015; Zhao et al., 2014). Whereas bothCell Stem Cell 25, 407–418, September 5, 2019 415
HSCs and megakaryocytes expand during aging, HSCs locate
further from megakaryocytes in adult Adrb3/ mice and proge-
roid mice, suggesting that decreased HSC-megakaryocyte in-
teractions might contribute to premature hematopoietic aging
features in these mice. Supporting this possibility, chronic treat-
ment of progeroid mice with b3-AR agonist decreased HSCs and
corrected lineage skewing, correlated with normalized distribu-
tion of HSCs near megakaryocytes. Future studies will be
required to investigate changes in the regulation of HSC prolifer-
ation by megakaryocytes during aging.
In summary, this study shows that the aged BMmicroenviron-
ment promotes myeloid expansion during physiological aging
and in premature aging. Normal murine aging concurs with the
reduction of endosteal niches and the expansion of non-endos-
teal niches comprising capillaries and nestin+ cells associated
with sympathetic noradrenergic fibers. Interestingly, b2-AR and
b3-AR regulate myelopoiesis through opposite and stage-
dependent effects on the hematopoietic microenvironment.
During normal aging, increased b2-AR activity promotes IL6-
dependent myeloid differentiation, whereas decreased b3-AR-
Nos1-NO is associated with reduced endosteal niches and
increased central niches. Adult Nos1 KO mice and progeroid
mice display premature aging in peripheral blood, manifested
as reduced lymphocytes and increased myeloid cells. Megakar-
yocytes move closer to BM sinusoids in Adrb3/ or progeroid
mice, possibly explaining increased thrombopoiesis. Megakar-
yocytes and HSCs expand but separate from each other during
normal aging and in adult Adrb3/ or progeroid mice. However,
chronic treatment of progeroid mice with b3-AR agonist reduces
HSCs and restores their proximity to megakaryocytes and their
lympho-myeloid skewing. Therefore, normal or premature niche
aging promotes normal myeloid expansion, which can be
improved by targeting the microenvironment.STAR+METHODS
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METHODS DETAILS
Mouse strains
Youngmicewere analyzed between 8-30weeks of age, and oldmicewere 66-120weeks old. Micewere housed in specific pathogen
free facilities. All experiments using mice followed protocols approved by the Animal Welfare Ethical Committees, according to EU
andUnited KingdomHomeOffice regulations (PPL 70/8406).Nes-gfp (Mignone et al., 2004),Adrb2/ (Chruscinski et al., 1999), FVB/
N-Adrb3tm1Lowl/J (Susulic et al., 1995), Lmnatm1.1Otin (Osorio et al., 2011), Vwf-egfp (Sanjuan-Pla et al., 2013), B6.129S4-
Nos1tm1Plh/J (stock#2986) (Huang et al., 1993), B6.129S2-Il6tm1Kopf/J (stock#2650) (Kopf et al., 1994) (Jackson Laboratories)
and congenic CD45.1 and CD45.2 C57BL/6 mice (Charles River Laboratories) were used in this study.
Mouse bone marrow transplantation and in vivo treatments
In LmnaG609G/G609G mouse model, HSC activity was assessed by long-term competitive repopulation assay using the congenic
CD45.1/CD45.2 isotypes. Recipient female CD45.1 C57BL/6 mice (8 week-old) were subjected to lethal irradiation (12 Gy whole
body irradiation, split dose 6.0 + 6.0 Gy, 3 h apart). 106 BM nucleated cells from (CD45.2) WT mice or LmnaG619G/G609G mice
were mixed with 106 BM nucleated cells from CD45.1 C57BL/6 mice and i.v. transplanted in 200 mL sterile PBS into lethally irradiated
CD45.1 C57BL/6 mice. At various time points after transplantation (4, 8, 12 and 16 weeks), peripheral blood nucleated cells were
collected from recipients. Cells were stained with fluorescent-conjugated antibodies against B220, Mac1 and CD90 antigens, and
analyzed by fluorescence-activated cell sorting. The selective b3-AR agonist BRL37344 (Sigma, St. Louis, MO) was administered
at 2mg/kg through intraperitoneal (i.p.) injection once per day. Vehicle (saline solution) daily injections were performed in the
same way. Treatment was initiated when LmnaG609G/G609G mice were 7 weeks old and lasted for 8 weeks.
To generate chimeric mice carrying Adrb2/ or Adrb3/ BM cells, two-month-old C57BL/6 mice were lethally irradiated (12 Gy,
two split doses) and i.v. transplanted with 2 X 106 nucleated BM cells from two-month-old WT, Adrb2/ or Adrb3/ mice. To test
microenvironment-dependent effects of b-adrenergic signaling, WT, Adrb2/ or Adrb3/ (CD45.2) mice were lethally irradiated
(12 Gy, two split doses) and i.v. transplanted with 2 X 106 nucleated BM cells from CD45.1 C57BL/6 mice. Hematopoietic cells in
the BM were analyzed 4 months after transplantation in both settings.
BM cell extraction, flow cytometry and fluorescence-activated cell sorting
For BM hematopoietic cell isolation, bones were crushed in a mortar, filtered through a 40-mm strainer to obtain single cell suspen-
sions, and depleted of red blood cells by lysis in 0.15 M NH4Cl for 10 min at 4
C. Blood samples were directly lysed. Cells were incu-
bated with the appropriate dilution (2-5 mg/ml) of fluorescent antibody conjugates and 4’,6-diamidino-2-phenylindole (DAPI) for dead
cell exclusion, and analyzed on LSRFortessa flow cytometer (BDBiosciences, Franklin Lakes, NJ) equippedwith FACSDiva SoftwareCell Stem Cell 25, 407–418.e1–e6, September 5, 2019 e3
(BD Biosciences). The following antibodies were used: fluorescent CD45.1 (A20), CD45.2 (104), B220 (RA3-6B2), CD11b (M1/70),
CD3ε (145-2C11), Ly-6G (1A8), CD90 (53-2.1) sca-1 (E13-161.7), CD42d (1C2), biotinylated lineage antibodies (CD11b, Gr-1,
Ter119, B220, CD3ε) (BD Biosciences), c-kit (2B8) (eBioscience), CD150 (TC15-12F12.2), CD34 (RAM34) and CD41 (MWReg30)
(BioLegend). Biotinylated antibodies were detected with fluorochrome conjugated streptavidin (BD Biosciences).
To isolate endosteal and non-endosteal HSPCs, long bones were flushed gently to obtain hematopoietic cells less tightly associ-
atedwith the bone and then flushed-bones were crushed in amortar to obtain hematopoietic cells enriched in the endosteal compart-
ment. Cells were stained with the above-mentioned antibodies and analyzed by flow cytometry or sorted (FACS Aria cell sorter, BD
Bioscience). Long-term HSCs (LT-HSCs) were immunophenotypically defined as lin-sca-1+ckit+CD34-CD150+CD41- cells.
Myeloid-biased HSCs were immunophenotypically defined as lin-sca-1+ckit+CD34-CD150+CD41+ cells. Lymphoid-biased HSCs
were immunophenotypically defined as lin-sca-1+ ckit+CD34-CD150-CD41- cells.
For analysis of Nes-GFP+ cell distribution in endosteal and non-endosteal BM fractions, the long bones were flushed with PBS and
remaining endosteal part was crushed in amortar. Both fractions were digested in 2ml of collagenase type I (StemCell Technologies,
cat. No. 07902) for 30 min at 37C with agitation. The enzyme was quenched by adding 18ml PBS/2%FCS. Cell suspensions were
filtered, pelleted and red blood cell lysis was performed as stated above. Samples were stained with the following antibodies: 1:100
anti-CD45-biotinylated ab (BD Biosciences, cat. No. 553078), 1:100 anti-Ter119 –biotinylated ab (BD Biosciences, cat. No. 553672),
1:100 anti-CD31-APC ab (BD Biosciences, cat. No. 551262). Subsequently, cells were stained with Streptavidin-APCCy7 1:200
(BD Biosciences, cat. No. 554063). DAPI (Sigma Aldrich, cat.no. D9542) was added at 1:10 000 to discriminate dead cells. Samples
were acquired on Gallios flow cytometer (Beckman Coulter) and a LSRFortessa cell analyzer (BD Biosciences) and were analyzed
with Kaluza analysis software (Beckman Coulter).
Cell culture
HPC-7 cells were maintained in IMDM medium supplemented with 10% FCS and 100 ng/ml of mSCF (PeProTech 250-03).
MS-5 cells were maintained in a-MEM medium supplemented with 10% FCS. To induce megakaryocyte differentiation, HPC-7
cells were cultured with or without MS-5 stromal cells in StemSpan H3000medium, supplemented with 50 ng/ml of TPO (PeProTech
300-18) and 2U/mL of EPO (R&D 287-TC-500) up to 4 days. 10 mM of BRL37344 (b3-AR agonist; Sigma B169), 10 mM of clenbuterol
(b2-AR agonist; SigmaC5423), 5 mMof H-89 (Protein kinase A inhibitor; Sigma B1427) and vehicle controls were added to the culture.
To examine megakaryocyte differentiation, cells were incubated with anti-ckit-FITC ab (1:200, BD PharMingen 553354) and anti-
CD41-PE ab (1:200, BD PharMingen 558040). DAPI was added at 1:10,000 to discriminate dead cells. Samples were analyzed by
Gallios flow cytometer (Beckman Coulter).
Human umbilical cord blood CD34+ HSPCs were isolated using a CD34 Microbead kit (Miltenyi Biotec 130-046-702) following
manufacturer’s instructions, and were cultured with MS-5 stromal cells in Cellgro medium (CellGenix cat. no. 20802-0500), supple-
mented with 50 ng/ml of TPO (PeProTech 300-18) and 5 ng/ml of IL-1b (Cellgenix 1411-050) for 7-10 days, during which vehicle,
10 mM of BRL37344 (b3-AR agonist; Sigma B169) or 10 mM of clenbuterol (b2-AR agonist; Sigma C5423) were added to the culture.
Conditioned medium was refreshed at day3 and day7 of the coculture. To examine megakaryocyte differentiation, cells were fixed
and stained with anti-human CD61 antibody (Serotec MCA 728).
For mouse bone marrow long-term culture, femurs and tibias were flushed gently to obtain bone marrow cells. Cells were seeded
and cultured inMyeloCult M5300medium (StemCell Technologies, cat. no. 05350) supplementedwith 106M hydrocortisone (Stem-
Cell Technologies, cat. no. 07904) at 33C for 14 days. Half of the medium was refreshed at day 7. At day 14 of culture, half of the
medium was refreshed again and added with 50 ng/ml of TPO (PeProTech 300-18) for 4 days, during which vehicle, 10 mM of
BRL37344 (b3-AR agonist; Sigma B169), 10 mM of clenbuterol (b2-AR agonist; Sigma C5423), or 100 mM of L-VINO (Insight Biotech-
nology 728944-69-2) were added to the culture. At day 18 of culture, cells were collected and subjected to flow cytometry analysis.
Immunofluorescence staining
Immunofluorescence staining of cryostat sections was performed as previously described (Isern et al., 2014), with minor
modifications. Briefly, tissues were permeabilized with 0.1% Triton X-100 (Sigma) for 10 min at RT and blocked with TNB buffer
(0.1 M Tris–HCl, pH 7.5, 0.15 M NaCl, 0.5% blocking reagent, Perkin Elmer) for 1 h at RT. Primary antibody incubations were con-
ducted for 2 h at RT. Secondary antibody incubations were conducted for 1 h at RT. Repetitive washes were performed with PBS +
0.05%Triton X-100. Stained tissue sections were counterstained for 5min with 5 mMDAPI and rinsedwith PBS. Slides weremounted
in Vectashield Hardset mounting medium (Vector Labs) and sealed with nail polish. Skull bones were fixed with 2% PFA for 2h in 4C,
washed with PBS and cut through the sagittal suture. Each half was permeabilized with PBS-0.1% Triton with 20% goat serum
(Thermo Scientific, cat. No. 9722) overnight at 4C on the rocker. Endogenous biotin was blocked with the Avidin/biotin blocking
kit (Vector Laboratories, cat. No. SP-2001) according to manufacturer’s recommendation. Endogenous peroxidase was blocked
with 0.4% peroxide (Sigma-Aldrich, cat. no. H1009) for 2h at RT. Subsequently, the skull bones were stained with rat anti-CD31
(BD Biosciences, cat. no. 551262) and rabbit anti-TH (Millipore, cat. no. AB152) in 0.1% Triton-20%goat serum-PBS (diluted
1:100 and 1:500 respectively) for 3 days, and washed over the next day with 0.05% Triton - PBS- at RT on a rocker. Samples
were stained with secondary goat anti-rat-Alexa647 at 1:300 (Life Technologies, cat. no. A21247) and goat anti-rabbit biotinylated
at 1:200 (Stratech Scientific, cat. no. 111-066-003) o/n at 4C. Subsequently, the skull bones were treated with ABC amplification
kit (Vector Labs) to detect Cy3-Tyrmide amplified signal from TH staining (Perkin Elmer, cat.no. SAT704A001EA). As a final step,
the skull bones were stained with DAPI 1:1000 for 5 min. Images were acquired with Leica TCS SP5 confocal microscope withe4 Cell Stem Cell 25, 407–418.e1–e6, September 5, 2019
10x objective. From each sample, 3 representative images were collected in different areas: frontal bone near bregma, central sinus
of parietal bone and interparietal bone near lambda. The TH+ area was analyzed with ImageJ. For whole mount staining of long
bones, tibia or femur BM thick sections were obtained with a cryostat and remaining OCT was removed by PBS washes. Samples
were blocked and permeabilized in 0.1% Triton X-100 (Sigma) TNB (0.1 M Tris–HCl, pH7.5, 0.15 M NaCl, 0.5% blocking reagent,
Perkin Elmer) overnight at 4C. On the next day, samples were incubated with rabbit anti-TH (Merck AB152; 1:200), goat anti-
CD31 (R&D AF3628 1:100), rat anti-EMCN (Insight Biotechnology sc-65495 1:100) or rat anti-CD31 (BD Biosciences Clone
MEC13.3; 1:200) diluted in 0.1% Triton X-100 TNB overnight at 4C. Samples were rinsed with 0.05% Triton X-100 PBS for 8 hours
and incubated overnight with secondary antibodies including A546 Donkey anti-rabbit IgG (Invitrogen A10040; 1:200), Dylight650
donkey anti-rat IgG (Thermo Fisher SA5-10029; 1:300), Cy3-donkey anti-goat IgG (Jackson 705-165-147, 1:300) diluted in TNB.
Samples were rinsed with 0.05% Triton X-100 PBS for 4 hours, washed with PBS and counterstained with DAPI (Sigma; 1:1000)
to label cell nuclei. Images were acquired with Leica SP5 confocal microscope using 10x, 20x and 40x objectives and analyzed
with ImageJ. At least 3 independent and randomly selected BM areas were imaged and analyzed per sample. To quantify neural fi-
bers, total TH+area was normalized per total BM area labeled with DAPI. For quantification of sinusoidal vessel area, EMCN+ area >
150 mm distant to the bone surface was measured and normalized to BM area. Arteriolar (> 6 mm diameter) and capillary (< 6 mm
diameter) CD31hiEMCN- vessel number was counted and normalized to BM area. To quantify transition zone vessels,
CD31hiEMCNhi area < 150 mm close to the bone surface was quantified and normalized to the bone surface length.
For staining of megakaryocyte andmegakaryocyte progenitor (Figures 3C–3F, 4J–4L, 5D–5F, 7G–7I, and S2A–S2D), BM femur thin
sections were blocked with TNB for 1h at RT. Samples were then incubated with primary antibodies for 2 h at RT or overnight at 4C,
followed by secondary antibodies incubation for 1h at RT. Finally, samples were counterstained with DAPI to label cell nuclei. Repet-
itive washes were performed with PBS. At least 3 independent and randomly selected BM areas were imaged and analyzed by
ImageJ. The following primary antibodies were used: CD41 (1:200, PE conjugated rat monoclonal antibody, BD PharMingen
558040), CD42d (1:100, APC conjugated armenian hamster monoclonal antibody, eBioscience 17-0421-80) and ckit (1:100, goat
polyclonal antibody, R&D AF1356). The following secondary antibodies were used: Alexa Fluor 647 Goat-anti-armenian
hamster IgG (1:200, Abcam ab173004) and Alexa Fluor 647 donkey-anti-goat IgG (1:200, Life Technologies A21447).
For staining of megakaryocyte localization relative to sinusoids (Figures 3I–3L and 5H–5J), BM femur thin sections were blocked
with 0.1% Triton X-100 TNB for 1h at RT. Samples were then incubated with rat anti-EMCN (Insight Biotechnology sc-65495 1:100)
antibody diluted in 0.1% Triton X-100 TNB overnight at 4C. On the next day, samples were incubated with Alexa Fluor 647 goat-anti-
rat IgG (1:200, Life Technologies, cat. no. A21247) secondary antibody for 1h at RT, followed by rat serum blocking (1:10 rat serum in
0.05% Triton X-100 TNB) for 10 min. Samples were incubated with third antibody, CD41 (1:200, PE conjugated rat monoclonal anti-
body, BD PharMingen 558040) for 2h at RT. Finally, samples were counterstained with DAPI to label cell nuclei. Repetitive washes
were performed with PBS or 0.05% Triton X-100 PBS. At least 3 independent and randomly selected BM areas were imaged and
analyzed by ImageJ.
For HSCs and megakaryocytes staining (Figures 7, S5, and S6), BM femur thin sections were blocked with TNB for 1h at RT and
followed by Avidin/biotin blocking. Samples were then incubated with rat anti-CD150 (1:50, Biolegend Cat. No. 115902) and arme-
nian hamster anti-CD42d (1:100, eBioscience 17-0421-80) primary antibodies overnight at 4C. On the next day, samples were incu-
bated with Alexa Fluor 555 goat-anti-rat IgG (1:200, Life Technologies A21434) and Alexa Fluor 647 Goat-anti-armenian hamster IgG
(1:200, Abcam ab173004) secondary antibodies for 1h at RT, followed by rat serum blocking (1:10 rat serum in TNB) for 10 min. Sam-
ples were re-stained with biotinylated lineage antibodies (1:100, BD Biosciences) for 2h at RT. Finally, samples were incubated with
Alexa Fluor 488 Streptavidin-conjugated antibody (1:200, Invitrogen S32354) for 1h at RT and counterstained with DAPI to label cell
nuclei. At least 3 independent and randomly selected BM areas were imaged and analyzed by ImageJ.
For staining of human cord blood CD34+ HSPC co-culture (Figures 4D and 4E), cells were fixed with 1%PFA for 20mins at RT. After
PBSwashes, cellswereblockedwith 10%donkeyserum (SigmaD9663)diluted inPBS for 1hatRT, followedby2h incubationofmouse-
anti-humanCD61primaryantibody (1:500,SerotecMCA728).AfterPBSwashes, cellswere incubatedwithAlexaFluor546donkey-anti-
mouse IgG (1:200, Life Technologies, cat. no. A10036) secondary antibody for 1h at RT. Finally, samples were counterstainedwith DAPI
to label cell nuclei. 10 independent and randomly selected fields in culture wells were imaged and analyzed by ImageJ.
RNA isolation and qPCR
RNA isolation was performed using Trizol Reagent (Sigma T9424). Reverse transcription was performed using the High-Capacity
cDNA Reverse Transcription kit (Applied Biosystems 4368814), following the manufacturer’s recommendations. qPCR was per-
formed using the PowerUp SYBR Green Master Mix (Applied Biosystems A25742) and ABI PRISM 7900HT Sequence Detection
System. The expression level of each gene was determined by using the absolute quantification standard curve method. All values
were normalized with Gapdh as endogenous housekeeping gene.
The following primers (mouse) were used:
NOS1-Fw: ACTGACACCCTGCACCTGAAGA
NOS1-Rv: GTGCGGACATCTTCTGACTTCC
NOS2-Fw: CAGCTGGGCTGTACAAACCTT
NOS2-Rv: CATTGGAAGTGAAGCGGTTCG
NOS3-Fw: CCTCGAGTAAAGAACTGGGAAGTGCell Stem Cell 25, 407–418.e1–e6, September 5, 2019 e5
e6NOS3-Rv: AACTTCCTTGGAAACACCAGGG
Gapdh-Fw: GCATGGCCTTCCGTGTTC
Gapdh-Rv: CTGCTTCACCACCTTCTTGATELISA
MILLIPLEX MAP Mouse Cytokine/Chemokine Magnetic Bead Panel (MCYTOMAG-70K, Merck Millipore) was performed following
the manufacture’s protocol. Extracellular fluids of mouse long bones were collected from the supernatants following BM extraction
and subjected to the mouse cytokine panel.
Measurement of nitrate concentration
NO(X) content was measured in freshly-thawed samples that had been kept at 80C for less than 2 months using a nitric oxide
analyzer (NOA) 280i (Siever, GE Healthcare) according to the manufacturer’s instructions. Data were collected, processed and
analyzed by using liquid software (Siever, GE Healthcare).
Statistical analyses
Statistical analyses and graphics were carried out with GraphPad Prism 5 software and Microsoft Excel.
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